- Home
- PHAR vs MRC Comparison
PHAR vs MRC Comparison
Compare PHAR & MRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- MRC
- Stock Information
- Founded
- PHAR 1988
- MRC 1921
- Country
- PHAR Netherlands
- MRC United States
- Employees
- PHAR N/A
- MRC N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- MRC Industrial Machinery/Components
- Sector
- PHAR Health Care
- MRC Industrials
- Exchange
- PHAR Nasdaq
- MRC Nasdaq
- Market Cap
- PHAR 1.0B
- MRC 1.1B
- IPO Year
- PHAR N/A
- MRC 2012
- Fundamental
- Price
- PHAR $14.60
- MRC $14.67
- Analyst Decision
- PHAR Strong Buy
- MRC Strong Buy
- Analyst Count
- PHAR 3
- MRC 3
- Target Price
- PHAR $30.00
- MRC $16.00
- AVG Volume (30 Days)
- PHAR 11.5K
- MRC 476.4K
- Earning Date
- PHAR 10-23-2025
- MRC 11-04-2025
- Dividend Yield
- PHAR N/A
- MRC N/A
- EPS Growth
- PHAR N/A
- MRC N/A
- EPS
- PHAR N/A
- MRC N/A
- Revenue
- PHAR $339,836,000.00
- MRC $2,945,000,000.00
- Revenue This Year
- PHAR $16.63
- MRC $5.81
- Revenue Next Year
- PHAR $6.77
- MRC $5.43
- P/E Ratio
- PHAR N/A
- MRC $38.88
- Revenue Growth
- PHAR 22.44
- MRC N/A
- 52 Week Low
- PHAR $7.06
- MRC $9.23
- 52 Week High
- PHAR $17.08
- MRC $15.59
- Technical
- Relative Strength Index (RSI)
- PHAR 57.37
- MRC 52.49
- Support Level
- PHAR $13.51
- MRC $14.48
- Resistance Level
- PHAR $15.61
- MRC $14.87
- Average True Range (ATR)
- PHAR 0.87
- MRC 0.37
- MACD
- PHAR -0.06
- MRC -0.05
- Stochastic Oscillator
- PHAR 59.37
- MRC 25.26
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About MRC MRC Global Inc.
MRC Global Inc distributes pipes, valves, fittings, and other infrastructure products and services to diversified gas utility, energy, and industrial end-markets. It provides supply chain solutions, technical product service and a digital platform for customers globally. It offers a range of PVF, oilfield supply, valve automation and modification, measurement, instrumentation, and other general and specialty products. Its geographical segments include the United States and International. It generates the majority of its revenue from the United States.